vaccine

FedEx Readies COVID-19 Vaccine Delivery Pipeline

By Brett Larson I FOXBusiness I
Article

The world is closer to a coronavirus vaccine after Pfizer and BioNTech disclosed, on Monday, that their treatment proved to be 90% effective in the first 94 patients it was tested on.

While there is still work to do, when the vaccine becomes available, FedEx will be ready to deliver millions and eventually billions of doses from the manufacturers to the consumer.

Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19

Summary: 

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Article

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
Press Release

NEW BRUNSWICK, N.J., September 28, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.

The Next Phase of Our COVID-19 Vaccine Development

by Alex Gorsky Chairman of the Board and Chief Executive Officer, Johnson & Johnson
Blog

It’s hard to believe that just six months have passed since our scientists identified Janssen’s lead COVID-19 vaccine candidate. We couldn’t have predicted all the changes that have happened since. Two things, however, have been constant: COVID-19 continues to be a devastating pandemic, and Johnson & Johnson has been working around the clock on a potential solution.

Johnson & Johnson Signs a Historic Pledge to Uphold the Integrity of the Scientific Process in Developing an Investigational COVID-19 Vaccine

In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.
Article

Recently, Johnson & Johnson announced that we, alongside eight other companies working on investigational COVID-19 vaccines, are signing a #WeStandWithScience pledge committed to upholding the integrity of the scientific process as we work towards potential global regulatory filings and approvals of the first vaccines for COVID-19.

The EU Commits €400M in Guarantees to Ensure Equitable Access to COVID-19 Vaccines

Summary: 
Why Global Citizens Should Care
The COVID-19 pandemic has not only caused a global health crisis, but also emergencies in education, hunger, and the economy. To prevent millions from falling back into poverty, the United Nations urges countries to come together to fight this virus and continue advancing toward the Global Goals. Join Global Citizen and take action here
Article
Why Global Citizens Should Care
The COVID-19 pandemic has not only caused a global health crisis, but also emergencies in education, hunger, and the economy. To prevent millions from falling back into poverty, the United Nations urges countries to come together to fight this virus and continue advancing toward the Global Goals. Join Global Citizen and take action here

4 Latest Facts About Johnson & Johnson's Investigational COVID-19 Vaccine

Summary: 

A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. We share more about the findings from the recent preclinical study, along with other up-to-date information about the potential vaccine candidate.

Blog

A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. We share more about the findings from the recent preclinical study, along with other up-to-date information about the potential vaccine candidate.

Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine With the Imbokodo Study

The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
Blog

Since the start of the pandemic, Johnson & Johnson has been working to help address the devastating impacts of COVID-19 through the power of its science, the size of its global reach—and the know-how that comes from such experiences as standing up to challenges like HIV.

“I Was Working on a Potential COVID-19 Vaccine—Then My Wife Got Sick”: Meet a Researcher Whose Personal Experience Is Fueling His Fight Against the Pandemic

Within a matter of weeks, Ramon Polo's work and home life were completely changed by the novel coronavirus—and he's a stronger scientist and husband for it.
Blog

In late January—weeks before many people had even heard of the novel coronavirus—Ramon Polo, PharmD, Ph.D., started to work on finding solutions to fight the virus, which data suggested had the potential to become a global pandemic.

As the Vice President of Regulatory Affairs for Infectious Diseases and Vaccines and Global Public Health at Johnson & Johnson, Dr. Polo quickly began to focus on working with healthcare authorities across the globe to collaborate on the development of both therapeutic treatments and a potential vaccine for the rapidly spreading novel coronavirus.

The Road to a Vaccine, Season 2, Ep. 2: How New COVID-19 Outbreaks Are Impacting a Global Return to Normal

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

In Episode 2, Lisa Ling talks with Dr. Francis Collins, Director, NIH about the latest on treatments and vaccines. Also, Harvard's Dr. Ashish Jha shares how the virus affects the body and Johns Hopkins' Dr. Tom Inglesby explains what the new data on spread means for people.

Pages

Subscribe to vaccine